Kallikrein-related peptidase 13 (KLK13) gene expressional status contributes significantly in the prognosis of primary gastric carcinomas

Clinical Biochemistry

Volumn 43, Issue 15, 2010, Pages 1205-1211

  Konstantoudakis, George ^a   Florou, Dimitra ^b   Mavridis, Konstantinos ^b   Papadopoulos, Iordanis N ^a   Scorilas, Andreas ^b  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Biomarker; Kallikrein related peptidases; KLK13; Prognosis; Stomach cancer patients' survival

Indexed keywords

BIOLOGICAL MARKER; KALLIKREIN RELATED PEPTIDASE 13; SERINE PROTEINASE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER RECURRENCE; DISEASE FREE SURVIVAL; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; STOMACH CARCINOMA; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KALLIKREINS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MIDDLE AGED; PROGNOSIS; REFERENCE STANDARDS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STOMACH; STOMACH NEOPLASMS;

EID: 77956714174     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2010.07.016     Document Type: Article

References (41)

1. Crew K.D., Neugut A.I. Epidemiology of gastric cancer. World J Gastroenterol 2006, 12:354-362.
2. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
3. Dicken B.J., Bigam D.L., Cass C., Mackey J.R., Joy A.A., Hamilton S.M. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg 2005, 241:27-39.
4. Wolfrum F., Vogel I., Fandrich F., Kalthoff H. Detection and clinical implications of minimal residual disease in gastro-intestinal cancer. Langenbecks Arch Surg 2005, 390:430-441.
5. Yokoyama H., Ikehara Y., Kodera Y., Ikehara S., Yatabe Y., Mochizuki Y., et al. Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis. Br J Cancer 2006, 95:1504-1513.
6. Del Favero G., Farinati F., Di Mario F., Plebani M., Basso D., Valiante F., et al. Tumour markers in gastrointestinal malignancies: an update. Eur J Cancer Prev 1992, 1(Suppl. 3):59-69.
7. Galizia G., Lieto E., Orditura M., Castellano P., Mura A.L., Imperatore V., et al. Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery. World J Surg 2007, 31:1458-1468.
8. Sumiyoshi Y., Kakeji Y., Egashira A., Mizokami K., Orita H., Maehara Y. Overexpression of hypoxia-inducible factor 1alpha and p53 is a marker for an unfavorable prognosis in gastric cancer. Clin Cancer Res 2006, 12:5112-5117.
9. Amour A., Bird M., Chaudry L., Deadman J., Hayes D., Kay C. General considerations for proteolytic cascades. Biochem Soc Trans 2004, 32:15-16.
10. Gratio V., Beaufort N., Seiz L., Maier J., Virca G.D., Debela M., et al. Kallikrein-related peptidase 4: a new activator of the aberrantly expressed protease-activated receptor 1 in colon cancer cells. Am J Pathol 2010, 176:1452-1461.
11. Yousef G.M., Chang A., Scorilas A., Diamandis E.P. Genomic organization of the human kallikrein locus on chromosome 19q13.3-q13.4. Biochem Bioph Res Commun 2000, 276:125-133.
12. Lundwall A., Band V., Blaber M., Clements J.A., Courty Y., Diamandis E.P., et al. A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. Biol Chem 2006, 387:637-641.
13. Yousef G.M., Diamandis E.P. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev 2001, 22:184-204.
14. Clements J., Hooper J., Dong Y., Harvey T. The expanded human kallikrein (KLK) gene family: genomic organisation, tissue-specific expression and potential functions. Biol Chem 2001, 382:5-14.
15. Borgono C.A., Michael I.P., Diamandis E.P. Human tissue kallikreins: physiologic roles and applications in cancer. Mol Cancer Res 2004, 2:257-280.
16. Borgono C.A., Diamandis E.P. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 2004, 4:876-890.
17. Diamandis E.P., Yousef G.M. Human tissue kallikreins: a family of new cancer biomarkers. Clin Chem 2002, 48:1198-1205.
18. Hoffman B.R., Katsaros D., Scorilas A., Diamandis P., Fracchioli S., Rigault de la Longrais I.A., et al. Immunofluorometric quantitation and histochemical localisation of kallikrein 6 protein in ovarian cancer tissue: a new independent unfavourable prognostic biomarker. Br J Cancer 2002, 87:763-771.
19. K. Mavridis, A. Scorilas, Prognostic value and biological role of the kallikrein-related peptidases in human malignancies. Future Oncol 6 269-285.
20. Yousef G.M., Chang A., Diamandis E.P. Identification and characterization of KLK-L4, a new kallikrein-like gene that appears to be down-regulated in breast cancer tissues. J Biol Chem 2000, 275:11891-11898.
21. Chang A., Yousef G.M., Jung K., Rajpert-De Meyts E., Diamandis E.P. Identification and molecular characterization of five novel kallikrein gene 13 (KLK13; KLK-L4) splice variants: differential expression in the human testis and testicular cancer. Anticancer Res 2001, 21:3147-3152.
22. Chang A., Yousef G.M., Scorilas A., Grass L., Sismondi P., Ponzone R., et al. Human kallikrein gene 13 (KLK13) expression by quantitative RT-PCR: an independent indicator of favourable prognosis in breast cancer. Br J Cancer 2002, 86:1457-1464.
23. Scorilas A., Borgono C.A., Harbeck N., Dorn J., Schmalfeldt B., Schmitt M., et al. Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker. J Clin Oncol 2004, 22:678-685.
24. Kurlender L., Borgono C., Michael I.P., Obiezu C., Elliott M.B., Yousef G.M., et al. A survey of alternative transcripts of human tissue kallikrein genes. Biochim Biophys Acta 2005, 1755:1-14.
25. Komatsu N., Takata M., Otsuki N., Toyama T., Ohka R., Takehara K., et al. Expression and localization of tissue kallikrein mRNAs in human epidermis and appendages. J Invest Dermatol 2003, 121:542-549.
26. Petraki C.D., Karavana V.N., Diamandis E.P. Human kallikrein 13 expression in normal tissues: an immunohistochemical study. J Histochem Cytochem 2003, 51:493-501.
27. Kapadia C., Chang A., Sotiropoulou G., Yousef G.M., Grass L., Soosaipillai A., et al. Human kallikrein 13: production and purification of recombinant protein and monoclonal and polyclonal antibodies, and development of a sensitive and specific immunofluorometric assay. Clin Chem 2003, 49:77-86.
28. Anon. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2000, 284:3043-3045.
29. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
30. Camp R.L., Dolled-Filhart M., Rimm D.L. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004, 10:7252-7259.
31. Altman D.G., Lausen B., Sauerbrei W., Schumacher M. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994, 86:829-835.
32. Siewert J.R., Bottcher K., Stein H.J., Roder J.D. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 1998, 228:449-461.
33. Scartozzi M., Bittoni A., Pistelli M., Galizia E., Berardi R., Giampieri R., et al. Toward molecularly selected chemotherapy for advanced gastric cancer: state of the art and future perspectives. Cancer Treat Rev 2009, 35:451-462.
34. Paliouras M., Borgono C., Diamandis E.P. Human tissue kallikreins: the cancer biomarker family. Cancer Lett 2007, 249:61-79.
35. Paliouras M., Diamandis E.P. The kallikrein world: an update on the human tissue kallikreins. Biol Chem 2006, 387:643-652.
36. Shaw J.L., Diamandis E.P. Distribution of 15 human kallikreins in tissues and biological fluids. Clin Chem 2007, 53:1423-1432.
37. Nagahara H., Mimori K., Utsunomiya T., Barnard G.F., Ohira M., Hirakawa K., et al. Clinicopathologic and biological significance of kallikrein 6 overexpression in human gastric cancer. Clin Cancer Res 2005, 11:6800-6806.
38. Feng B., Xu W.B., Zheng M.H., Ma J.J., Cai Q., Zhang Y., et al. Clinical significance of human kallikrein 10 gene expression in colorectal cancer and gastric cancer. J Gastroenterol Hepatol 2006, 21:1596-1603.
39. Kapadia C., Yousef G.M., Mellati A.A., Magklara A., Wasney G.A., Diamandis E.P. Complex formation between human kallikrein 13 and serum protease inhibitors. Clin Chim Acta 2004, 339:157-167.
40. Heidtmann H.H., Nettelbeck D.M., Mingels A., Jager R., Welker H.G., Kontermann R.E. Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen. Br J Cancer 1999, 81:1269-1273.
41. Sotiropoulou G., Rogakos V., Tsetsenis T., Pampalakis G., Zafiropoulos N., Simillides G., et al. Emerging interest in the kallikrein gene family for understanding and diagnosing cancer. Oncol Res 2003, 13:381-391.